Oral Norovirus Vaccine Pill Shows Promise in Early Trials
An oral vaccine pill for norovirus has shown promising results in early clinical trials, demonstrating strong immune responses and safety in varied age groups. Further studies are underway to validate these early findings.
Published on April 14, 2025
A new oral vaccine for norovirus, often referred to as the winter vomiting bug, has shown promising safety and immune response results in its early clinical trials. The vaccine, which is administered in pill form, elicited strong systemic and mucosal immune responses, especially noted in studies involving older adults. Early Phase 1 and Phase 1b trials conducted in early 2025, notably on February 8 and March 2025, have confirmed its tolerability and robust immunogenicity.
Building on these encouraging findings, companies like Vaxart, Inc. are comparing different vaccine constructs to improve protective responses. Further studies are planned to confirm both the efficacy and long-term safety of this innovative approach, with topline results expected later in 2025. The ongoing research continues to provide insights into the vaccine's potential role in combating norovirus outbreaks during the winter months.